Skip to main content

Posts

Showing posts with the label orthoebolavirus

RAPID #RISK #ASSESSMENT: #EBOLA VIRUS DISEASE, DRC (#WHO, September 19 '25)

  {Summary} Overall risk and confidence Overall risk -- National: High  -- Regional: Moderate    -- Global: Low    Confidence in available information  -- National: Moderate -- Regional: Moderate -- Global: Moderate Risk statement On 1 September 2025, WHO received an alert from the Ministry of Health of the Democratic Republic of the Congo (DRC) regarding suspected cases of Ebola virus disease (EVD) in the Bulape Health Zone , Kasai Province , DRC.  The first currently known suspected EVD case was admitted to the Bulape General Reference Hospital on 20 August 2025 and reported to have died five days later (25 August 2025). This is a 34-year-old female patient with a 34-week gestational age who presented with fever, bloody diarrhoea, followed by anal, oral, and nasal haemorrhage, vomiting , and asthenia .  She reportedly died on 25 August 2025, with a clinical picture of multiple organ failure.  Two of the contacts of this first case (a m...

Heterologous two-dose #Ebola #vaccine regimen in #pregnant women in #Rwanda: a randomized controlled phase 3 trial

  Abstract Risk of death for both mother and fetus following Ebola virus infection is extremely high . In this study, healthy women in Rwanda aged ≥18 years were randomized to two-dose Ebola vaccination (Ad26.ZEBOV, MVA-BN-Filo) during pregnancy (group A) or postpartum (group B). Unvaccinated pregnant group B women served as control. This was a parallel, randomized, controlled, open-label, single-center trial to evaluate the safety (primary endpoint—outcomes of interest and serious adverse events (SAEs)) and immunogenicity (secondary endpoint) of the two-dose Ebola vaccination. Among 3,484 women screened, 2,013 were randomized, and 2,012 women and 1,945 infants born alive were descriptively analyzed . Adverse outcomes of interest occurred in women ( 5.2% in group A and 7.3% in group B ) and infants ( 26.0% in group A and 25.6% in group B ). The most common maternal outcome of interest was pathways to preterm birth (3.2% in group A and 3.4% in group B), and the most common infant ou...

#Thermal #tolerance and #inactivation of #Ebola virus

{Summary} HIGHLIGHTS •  The investigation demonstrated a high level of tolerance of EBOV to thermal disinfection. •  A water-bath is recommended and the tubes should be fully submerged during the process. •  The established inactivation guidelines should be followed very strictly. Dear Editor, Viruses of the genus Orthoebolavirus cause sporadic outbreaks of severe haemorrhagic fever, with case fatality rates ranging from 25% to 90% (Mahanty and Bray, 2004). Six species of the virus (Orthoebolavirus zairense, sudanense, bundibugyoense, taiense, restonense, and bombaliense) have so far been identified (Biedenkopf et al., 2023). Among these, Orthoebolavirus zairense , commonly known as Ebola virus (EBOV), stands out as the most virulent . Given its high contagiousness and lethality, EBOV must be manipulated under biosafety level 4 (BSL-4) conditions, as stipulated by the National Health Commission of the People's Republic of China's list of human pathogenic microorganisms. P...